A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
The change to a single-dose HPV vaccine has led to more girls in Doncaster receiving the jab in the last school year, new figures suggest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback